Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 8, 2012, Pages 1125-1134

  Zivadinov, R ^a,b   Dwyer, M G ^a   Hussein, S ^a   Carl, E ^a   Kennedy, C ^a   Andrews, M ^a   Hojnacki, D ^a   Heininen Brown, M ^a   Willis, L ^a   Cherneva, M ^a   Bergsland, N ^a   Weinstock Guttman, B ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

clinical trials observational study; MRI; multiple sclerosis; voxel wise MTR

Indexed keywords

BETA1A INTERFERON; NATALIZUMAB;

ADULT; ARTICLE; BRAIN SIZE; CONTROLLED STUDY; DEMYELINATION; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REMYELINIZATION; VOXEL BASED MORPHOMETRY; WHITE MATTER;

EID: 84864121213     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511433304     Document Type: Article

References (29)

1. Bruck W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol. 2005 ; 252 (Suppl. 5). v3-9
2. Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?. Neurology. 2007 ; 68: S72 - S82
3. Bellmann-Strobl J, Stiepani H, Wuerfel J, et al. MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol. 2009 ; 19: 2066-2074
4. Deloire MS, Salort E, Bonnet M, et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005 ; 76: 519-526
5. Khaleeli Z, Altmann DR, Cercignani M, et al. Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis. Arch Neurol. 2008 ; 65: 1454-1459
6. Vrenken H, Pouwels PJ, Ropele S, et al. Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Mult Scler. 2007 ; 13: 708-716
7. Deloire-Grassin MS, Brochet B, Quesson B, et al. In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J Neurol Sci. 2000 ; 178: 10-16
8. Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol. 2003 ; 60: 1073-1081
9. Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004 ; 56: 407-415
10. Dwyer M, Bergsland N, Hussein S, et al. A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratio. J Neurol Sci. 2009 ; 282: 86-95
11. Chen JT, Collins DL, Freedman MS, et al. Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients. Neuroimage. 2005 ; 25: 1272-1278
12. Chen JT, Collins DL, Atkins HL, et al. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol. 2008 ; 63: 254-262
13. Chen JT, Kuhlmann T, Jansen GH, et al. Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage. 2007 ; 36: 1152-1158
14. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003 ; 348: 15-23
15. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007 ; 68: 1390-1401
16. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
17. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 911-923
18. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol. 2004 ; 251: 407-413
19. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005 ; 58: 840-846
20. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 ; 46: 907-911
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
22. Foley J. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis. Am J Manag Care. 2010 ; 16: S178 - S183
23. Zivadinov R, Bagnato F, Nasuelli D, et al. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. J Neurol Sci. 2004 ; 223: 185-193
24. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology. 2001 ; 57: 1239-1247
25. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009 ; 44: 83-98
26. Giacomini PS, Levesque IR, Ribeiro L, et al. Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. Arch Neurol. 2009 ; 66: 375-381
27. Mufson EJ, Kroin JS, Sendera TJ, et al. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol. 1999 ; 57: 451-484
28. Von Bartheld CS, Fritzsch B. Comparative analysis of neurotrophin receptors and ligands in vertebrate neurons: tools for evolutionary stability or changes in neural circuits?. Brain Behav Evol. 2006 ; 68: 157-172
29. TYSABRIU. TYSABRI US (prescribing information), 2011.